Codexis, Inc. (NASDAQ:CDXS) Shares Bought by Vanguard Group Inc.

Vanguard Group Inc. grew its position in shares of Codexis, Inc. (NASDAQ:CDXS - Free Report) by 7.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 4,463,801 shares of the biotechnology company's stock after acquiring an additional 311,082 shares during the quarter. Vanguard Group Inc. owned about 5.49% of Codexis worth $21,292,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Tallon Kerry Patrick acquired a new stake in Codexis in the 4th quarter valued at $2,018,000. Telemark Asset Management LLC boosted its position in shares of Codexis by 11.3% in the fourth quarter. Telemark Asset Management LLC now owns 3,000,000 shares of the biotechnology company's stock worth $14,310,000 after buying an additional 303,589 shares during the period. Inspire Investing LLC acquired a new stake in shares of Codexis in the fourth quarter valued at about $405,000. Monimus Capital Management LP purchased a new stake in shares of Codexis during the 4th quarter valued at about $339,000. Finally, Barclays PLC lifted its position in Codexis by 51.1% during the 3rd quarter. Barclays PLC now owns 207,628 shares of the biotechnology company's stock worth $640,000 after acquiring an additional 70,255 shares in the last quarter. 78.54% of the stock is currently owned by hedge funds and other institutional investors.

Codexis Stock Down 0.5 %

NASDAQ CDXS traded down $0.01 on Friday, reaching $2.11. The company had a trading volume of 557,169 shares, compared to its average volume of 658,907. The company has a debt-to-equity ratio of 0.39, a current ratio of 3.21 and a quick ratio of 3.15. Codexis, Inc. has a 1 year low of $1.90 and a 1 year high of $6.08. The firm has a 50-day moving average of $2.93 and a 200-day moving average of $3.85. The firm has a market capitalization of $174.79 million, a PE ratio of -2.43 and a beta of 2.35.

Codexis (NASDAQ:CDXS - Get Free Report) last announced its earnings results on Thursday, February 27th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.09). Codexis had a negative net margin of 96.35% and a negative return on equity of 71.56%. The firm had revenue of $21.46 million during the quarter, compared to analysts' expectations of $27.41 million. On average, equities research analysts anticipate that Codexis, Inc. will post -0.77 EPS for the current fiscal year.

Codexis Profile

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.